Startup profile · funding coverage
Arda Therapeutics
Targeted cell-depletion therapies for chronic diseases using oncology modalities outside cancer.
Stage
series a
Status
private
Coverage
full
Why Arda Therapeutics is interesting
Applying ADC and T-cell engager approaches to fibrosis and immunology — single-cell biology engine to selectively remove pathogenic cell populations.
Key facts
- Series A (2024): $43M led by a16z with Two Sigma Ventures, GV, Eli Lilly (Business Wire)
- Seed (2022): a16z Bio + Health led at inception (a16z announcement)
- Thesis: ADC/TCE cell depletion for fibrosis and immunology beyond oncology (Arda site)
- Co-investors not in VCT directory: GV (Google Ventures), Eli Lilly
Investors in our directory
Funds linked from Arda Therapeutics's profile — open a fund page for stage focus and related deal articles.
Industries
Biotech & Life Sciences
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover Arda Therapeutics's financing or category context.
FAQs about Arda Therapeutics
Funding context and why this company shows up in venture coverage.
Arda Therapeutics develops targeted cell-depletion therapies — using ADC and T-cell engager approaches from oncology — to selectively remove pathogenic cells in chronic diseases like fibrosis and immunology.
Directory-linked investors include Andreessen Horowitz (/fund/andreessen-horowitz), Two Sigma Ventures (/fund/two-sigma-ventures), and First Round (/fund/first-round). GV and Eli Lilly participated in the Series A.
Arda raised a $43M Series A in 2024 after a 2022 a16z-led seed — a clinical-stage biotech company.
Many chronic diseases are driven by specific pathogenic cell populations. Arda applies proven oncology depletion modalities to non-oncology indications — a precision medicine bet beyond broad immunosuppression.
No — Arda Therapeutics remains a private company as of July 2026.
Last updated: 2026-07-24